ASND in the 13F filings
Ascendis Pharma A · CUSIPs 04351P101, K08588103
- Quarter end
- 31 Mar 2025
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 2 May 2025
- Managers listing it
- 13
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q4 2024 and Q1 2025; 10 listed it in both
- Shares listed
- 20,479,564
- combined, among listed positions
- Reported value
- $3.2bn
- combined, at the quarter end
Among the 95 comparable managers: 7 buyers (opened or added shares) and 6 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing ASND in Q1 2025
13 of 13 holders
Largest increases and reductions, by shares
Increases
- Janus Henderson Group Ltdexisting position · 4,486,949 shares now+106,567
- Moore Capital Management LPexisting position · 90,000 shares now+70,000
- Point72 Asset Management LPexisting position · 569,146 shares now+65,477
- Voloridge Investment Management LLCexisting position · 346,018 shares now+47,022
- MFS Investment Managementexisting position · 1,877,917 shares now+10,366
Reductions
- Artisan Partners LPexisting position · 4,256,627 shares now-193,793
- Schonfeld Strategic Advisors LLCexisting position · 60,375 shares now-78,218
- Fidelity (FMR LLC)existing position · 4,672,943 shares now-55,704
- T. Rowe Price Associates Incexisting position · 2,256,102 shares now-27,105
- Woodline Partners LPexisting position · 304,806 shares now-12,836
New positions and exits
New (1)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2017 | 1 | $2.1m | n.a. | n.a. |
| Q3 2017 | 2 | $4.7m | n.a. | n.a. |
| Q4 2017 | 1 | $4.8m | n.a. | n.a. |
| Q1 2018 | 6 | $362m | n.a. | n.a. |
| Q2 2018 | 4 | $310m | n.a. | n.a. |
| Q3 2018 | 3 | $359m | n.a. | n.a. |
| Q4 2018 | 4 | $638m | n.a. | n.a. |
| Q1 2019 | 8 | $1.7bn | n.a. | n.a. |
| Q2 2019 | 8 | $1.9bn | n.a. | n.a. |
| Q3 2019 | 8 | $1.7bn | n.a. | n.a. |
| Q4 2019 | 12 | $2.8bn | n.a. | n.a. |
| Q1 2020 | 9 | $2.3bn | n.a. | n.a. |
| Q2 2020 | 8 | $3.2bn | n.a. | n.a. |
| Q3 2020 | 9 | $4.1bn | n.a. | n.a. |
| Q4 2020 | 12 | $4.5bn | n.a. | n.a. |
| Q1 2021 | 10 | $3.4bn | n.a. | n.a. |
| Q2 2021 | 10 | $3.4bn | n.a. | n.a. |
| Q3 2021 | 10 | $4.5bn | n.a. | n.a. |
| Q4 2021 | 11 | $3.7bn | n.a. | n.a. |
| Q1 2022 | 10 | $3.3bn | n.a. | n.a. |
| Q2 2022 | 9 | $2.5bn | n.a. | n.a. |
| Q3 2022 | 12 | $2.7bn | n.a. | n.a. |
| Q4 2022 | 12 | $3.0bn | n.a. | n.a. |
| Q1 2023 | 9 | $2.6bn | n.a. | n.a. |
| Q2 2023 | 8 | $1.9bn | n.a. | n.a. |
| Q3 2023 | 8 | $2.0bn | n.a. | n.a. |
| Q4 2023 | 11 | $2.8bn | 5 | 7 |
| Q1 2024 | 16 | $3.4bn | 10 | 6 |
| Q2 2024 | 14 | $2.8bn | 8 | 7 |
| Q3 2024 | 15 | $3.1bn | 11 | 5 |
| Q4 2024 | 11 | $2.6bn | 6 | 7 |
| Q1 2025 | 13 | $3.2bn | 7 | 6 |
| Q2 2025 | 11 | $3.2bn | 5 | 6 |
| Q3 2025 | 15 | $3.7bn | 6 | 8 |
| Q4 2025 | 14 | $3.7bn | 16 | 14 |
| Q1 2026 | 10 | $3.1bn | 7 | 25 |
| Q2 2026 | 12 | $4.3bn | 19 | 9 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
ASND and LLY →ASND and JNJ →ASND and VRTX →Choose a stock to compare with ASND →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own ASND, latest filings →Back to the 13F Explorer →